Perspectives of decreasing individual cardiovascular risk in high- and very high risk patients with arterial hypertension, treated with rilmenidine
| Autor: | S. V. Nedogoda, I. V. Marchenko, T. A. Chalyabi, U. A. Brel, V. A. Tsoma, E. A. Prokhorova, E. S. Kesareva |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2005 |
| Předmět: | |
| Zdroj: | Кардиоваскулярная терапия и профилактика, Vol 4, Iss 3, ч.I, Pp 40-45 (2005) |
| Druh dokumentu: | article |
| ISSN: | 1728-8800 2619-0125 |
| Popis: | Aim. To assess perspectives of decreasing individual cardiovascular event (CVE) risk and surrogate end-point incidence (blood pressure, BP; left ventricular hypertrophy, LVH; pulse wave velocity, PWV), in high- and very high-risk patients with Stage II-III arterial hypertension (AH), during 6-month rilmenidine monotherapy. Material and methods. This open clinical trial included 20 high- and very high-risk patients (6 males and 14 females; mean age 63.2±10.4 years), with Stage II-II AH, who were administered rilmenidine, 2 mg/d, for 6 months. At baseline and in the end of the treatment phase, all participants underwent 24-hour blood pressure monitoring (BPM), echocardiography (EchoCG), PWV measurement, biochemical examination, and individual CVE risk assessment by Framingham Scale. Results. After 6 months of rilmenidine monotherapy, target BP level was achieved in 78% of the patients. According to 24-hour BPM results, mean circadian systolic and diastolic blood pressure (SPB, DBP) levels had decreased by 10.5% and 7.4% (р |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|